株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

肝硬変 : パイプライン製品の分析

Liver Cirrhosis - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 213038
出版日 ページ情報 英文 90 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.65円で換算しております。
Back to Top
肝硬変 : パイプライン製品の分析 Liver Cirrhosis - Pipeline Review, H2 2017
出版日: 2017年08月16日 ページ情報: 英文 90 Pages
概要

肝硬変とは、各種の肝臓病・疾患(肝炎・慢性アルコール中毒など)が原因で発症する、肝臓の瘢痕状態のことを指します。瘢痕組織により肝臓の正常構造が損傷され、更には肝臓内の血流にも悪影響が及ぼします。主な症状として、食欲不振や皮膚の痒み、体重減少、疲労感、吐き気などが挙げられます。主な治療法には肝移植手術などがあります。

当レポートでは、世界各国での肝硬変治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査して、その結果をお届けします。

目次

イントロダクション

  • 分析範囲

肝硬変の概要

治療薬の開発

  • 肝硬変向けパイプライン製品:概要
  • 肝硬変向けパイプライン製品:比較分析

各企業で開発中の肝硬変治療薬

大学/研究機関で研究中の肝硬変治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

肝硬変治療薬:開発中の製品の一覧(企業別)

肝硬変治療薬:研究中の製品の一覧(大学/研究機関別)

肝硬変治療薬の開発に従事している企業

  • Conatus Pharmaceuticals Inc.
  • Digna Biotech, S.L.
  • Galectin Therapeutics, Inc.
  • Human Stem Cells Institute
  • Nimbus Therapeutics, LLC
  • Ocera Therapeutics, Inc.
  • Pharmicell Co., Ltd.
  • S-Evans Biosciences, Inc.
  • Stelic Institute & Co., Inc.

肝硬変:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

肝硬変治療薬:開発が休止状態の製品

肝硬変治療薬:開発が中止された製品

肝硬変関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9630IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H2 2017, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape.

Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Cirrhosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Liver Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Liver Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 3, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Liver Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Cirrhosis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Liver Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Liver Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Liver Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Liver Cirrhosis (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Liver Cirrhosis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Liver Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Liver Cirrhosis - Overview
    • Liver Cirrhosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Liver Cirrhosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Liver Cirrhosis - Companies Involved in Therapeutics Development
    • Conatus Pharmaceuticals Inc
    • Galectin Therapeutics Inc
    • Gilead Sciences Inc
    • Human Stem Cells Institute
    • Immunitor Inc
    • International Stem Cell Corp
    • Ocera Therapeutics Inc
    • Pharmicell Co Ltd
    • VESSL Therapeutics Ltd
  • Liver Cirrhosis - Drug Profiles
    • BCD-800 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cell Therapy for Liver Cirrhosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellgram-LC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • emricasan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gemacell - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GMCT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GRMD-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GXHPC-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ND-654 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ornithine phenylacetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NLRP3 for Liver Cirrhosis and Non-Alcoholic Steatohepatitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage, Liver Cirrhosis, Pneumoconiosis and Rheumatoid Arthritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy to Activate ZSCAN4 for Liver Cirrhosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • V-5 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Liver Cirrhosis - Dormant Projects
  • Liver Cirrhosis - Discontinued Products
  • Liver Cirrhosis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 16, 2017: Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference
      • Nov 14, 2016: Conatus Announces Poster Presentations at AASLD Annual Meeting
      • Nov 03, 2016: Conatus Initiates Phase 2b ENCORE-PH Clinical Trial of Emricasan in Patients with NASH Cirrhosis
      • May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial
      • Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data
      • Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting
      • Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial
      • Nov 16, 2015: Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting
      • Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting
      • Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting
      • Oct 01, 2015: Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting
      • Jun 25, 2015: Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement
      • May 14, 2015: Galectin Therapeutics Reports no Drug-Drug Interaction Between GR-MD-02 and Midazolam
      • Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting
      • Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Liver Cirrhosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Liver Cirrhosis - Pipeline by Conatus Pharmaceuticals Inc, H2 2017
  • Liver Cirrhosis - Pipeline by Galectin Therapeutics Inc, H2 2017
  • Liver Cirrhosis - Pipeline by Gilead Sciences Inc, H2 2017
  • Liver Cirrhosis - Pipeline by Human Stem Cells Institute, H2 2017
  • Liver Cirrhosis - Pipeline by Immunitor Inc, H2 2017
  • Liver Cirrhosis - Pipeline by International Stem Cell Corp, H2 2017
  • Liver Cirrhosis - Pipeline by Ocera Therapeutics Inc, H2 2017
  • Liver Cirrhosis - Pipeline by Pharmicell Co Ltd, H2 2017
  • Liver Cirrhosis - Pipeline by VESSL Therapeutics Ltd, H2 2017
  • Liver Cirrhosis - Dormant Projects, H2 2017
  • Liver Cirrhosis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Liver Cirrhosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Top 10 Stage and Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top